In December 2025, an international multispecialty consensus guideline on sacroiliac joint complex pain was published in the ...

SPRING HOUSE, PA — Johnson & Johnson’s TREMFYA met the primary and major secondary endpoints in a Phase 4 trial of adults with psoriatic arthritis and axial involvement, showing improvements ...

Johnson & Johnson phase 4 STAR study of Tremfya meets the primary and major secondary endpoints: Spring House, Pennsylvania Monday, September 28, 2026, 18:00 Hrs [IST] Johnson & J ...

When Professor Lee Eun-young of the Department of Rheumatology at Seoul National University Hospital sees a patient, she ...

Johnson & Johnson ( JNJ ), a healthcare company with a broad immunology portfolio, announced topline results from the Phase 4 STAR study showing that TREMFYA (guselkumab) improved axial symptoms and ...

Johnson & Johnson JNJ announced positive findings from key clinical evaluations testing its therapies, Tremfya and Carvykti, ...

Johnson & Johnson (NYSE:JNJ) said its Tremfya treatment significantly improved spinal pain and stiffness in adults with axial ...

Johnson & Johnson recently received U.S. Food and Drug Administration (FDA) approval of a label expansion for the inhibition of progression of structural joint damage in adults with active PsA, ...

Johnson & Johnson (NYSE:JNJ) says TREMFYA met Phase 4 STAR study endpoints in adults with axial psoriatic arthritis.

The other day, a high school student came to the clinic after experiencing worsening lower back pain following a game of long ...

AS patients wait 8–11 years for a correct diagnosis, often dismissed as back pain. Here's why the delay happens — and how AI research is closing it.

Scientists have redesigned a key piece of MRI hardware using metamaterials, allowing existing scanners to produce clearer images of difficult-to-see parts of the body in less time. The breakthrough ...